docetaxel anhydrous has been researched along with n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide in 4 studies
| Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide) | Trials (n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide) | Recent Studies (post-2010) (n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide) |
|---|---|---|---|---|---|
| 12,110 | 3,216 | 6,920 | 1,220 | 3 | 229 |
| Protein | Taxonomy | docetaxel anhydrous (IC50) | n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide (IC50) |
|---|---|---|---|
| Prostaglandin E synthase | Homo sapiens (human) | 10 | |
| Prostaglandin G/H synthase 1 | Ovis aries (sheep) | 2.1 | |
| Aromatase | Homo sapiens (human) | 0.68 | |
| Prostaglandin G/H synthase 1 | Mus musculus (house mouse) | 1.67 | |
| Prostaglandin G/H synthase 1 | Homo sapiens (human) | 3 | |
| Prostaglandin G/H synthase 2 | Homo sapiens (human) | 0.9037 | |
| Prostaglandin G/H synthase 2 | Ovis aries (sheep) | 2.4333 | |
| Prostaglandin G/H synthase 2 | Mus musculus (house mouse) | 0.1522 | |
| Carboxypeptidase B2 | Homo sapiens (human) | 1.8 | |
| Prostaglandin E synthase | Mus musculus (house mouse) | 0.007 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, AP; Kucera, GL; Miller, BE | 1 |
| Ali-Fehmi, R; Elhammady, E; Jiang, JZ; Malone, JM; Munkarah, AR; Saed, GM | 1 |
| Asano, K; Ito, Y; Kim, S; Matsukawa, N; Yamamoto, K; Yamatodani, A | 1 |
| Lin, J; Pan, W; Shi, H; Wu, H; Yu, H; Zhu, J | 1 |
4 other study(ies) available for docetaxel anhydrous and n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide
| Article | Year |
|---|---|
Cyclooxygenase inhibition and hyperthermia for the potentiation of the cytotoxic response in ovarian cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Docetaxel; Drug Synergism; Female; Humans; Hyperthermia, Induced; Nitrobenzenes; Ovarian Neoplasms; Sulfonamides; Taxoids; Tumor Cells, Cultured | 2007 |
The effects of combining docetaxel and cyclooxygenase-2 inhibitors on proliferation and apoptosis in epithelial ovarian cancer.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; bcl-2-Associated X Protein; Carcinoma; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; DNA Primers; Docetaxel; Female; Genes, bcl-2; Humans; In Situ Nick-End Labeling; Nitrobenzenes; Ovarian Neoplasms; RNA, Messenger; RNA, Neoplasm; Sulfonamides; Taxoids | 2007 |
Involvement of hypothalamic cyclooxygenase-2, interleukin-1β and melanocortin in the development of docetaxel-induced anorexia in rats.
Topics: Animals; Anorexia; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Docetaxel; Hypothalamus; Indomethacin; Interleukin-1beta; Male; Neoplasms; Nitrobenzenes; Pro-Opiomelanocortin; Pyrazoles; Rats; Rats, Wistar; Sulfonamides; Taxoids | 2012 |
Combined inhibition of epidermal growth factor receptor and cyclooxygenase-2 leads to greater anti-tumor activity of docetaxel in advanced prostate cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Death; Cell Proliferation; Cyclooxygenase 2; Docetaxel; ErbB Receptors; Flow Cytometry; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Male; Matrix Metalloproteinase 9; Mice; Mice, Inbred BALB C; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; NF-kappa B; Nitrobenzenes; Prostatic Neoplasms; Quinazolines; Sulfonamides; Taxoids; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2013 |